BMS acquires Padlock Therapeutics

Bristol-Myers Squibb announced that the company will acquire all of the outstanding capital stock of Padlock Therapeutics, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. The acquisition will give Bristol-Myers Squibb full rights to Padlock�s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis (RA). Padlock�s PAD discovery program may have additional utility in treating systemic lupus erythematosus (SLE) and other autoimmune diseases.